Cord blood (CB) and autologous mobilized peripheral blood stem/progenitor cells (PBSC) are now used widely for clinical transplantation. We characterized the short-term (Ͻ8 weeks) and long-term (Ͼ8 weeks) engraftment in NOD/SCID mice resulting from transplanted CD34 ϩ cells from these two sources. We also quantified the frequency of long-term engrafting cells, and the average proliferative capacity of individual engrafting cells by a competitive repopulation assay with binomial variance-covariance modeling. We found that 0.5 million CD34 ϩ CB cells were able to generate sustained, high-level, multilineage human hematopoiesis, whereas a sixfold higher number of CD34 ϩ PBSC (3 million) from cancer patients undergoing chemotherapy generated comparable short-term, but much lower sustained multilineage human hematopoiesis after transplantation. In comparison to CD34 ϩ cells from
INTRODUCTION
Cord blood (CB) and autologous mobilized peripheral blood stem/progenitor cells (PBSC) are used widely as alternative sources for hematopoietic cell transplantation grafts [1] [2] [3] . A patient and physician may be faced with a choice between (allogeneic) CB or (autologous) PBSC as a source of stem/progenitor cells for a therapeutic transplant. However, comparative clinical information is still limited on the long-term clinical engraftment capacity of hematopoietic cells from these two sources and the clinical information is not quantitative [2] [3] [4] . Large autologous PBSC harvests collected from adult cancer patients on chemotherapy usually contain large numbers of CD34 ϩ cells (ϳ10 8 -10 9 in a typical PBSC transplant graft preparation), but the long-term proliferative capacity of the stem/progenitor cells in PBSC collections may be reduced by prior chemotherapy or cytokine therapy [5] [6] [7] . In comparison, CB collections from healthy newborns contain many fewer total cells and total CD34
ϩ cells (ϳ10 6 -10 7 CD34 ϩ cells in a typical CB transplant graft preparation), but the CB stem/progenitor cells might have higher proliferative capacity (because younger individuals may have more potent or earlier stem/progenitor cells, or CB donors have not received chemotherapy or other treatment or both). Thus far, all available in vitro hematopoietic assays fail to measure long-term repopulating ability or lymphohematopoietic differentiating ability, the most important characteristics of long-term repopulating cells [8] . The use of human clinical gene marking trials to determine the contribution of autologous PBSC to long-term engraftment is technically demanding and not yet quantitative because of the low efficiency of gene transfer [4] . Recently, sublethally irradiated nonobese diabetic-scid/scid (NOD/SCID) mice have been found to support the growth of transplanted human hematopoietic cells [9] . Using limiting dilution
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Wing Leung, 1, 2 Manuel Ramírez, 1 Curt I. Civin analysis with the NOD/SCID xenotransplant model, Wang et al. found that the frequency of engrafting cells at 4-6 weeks after transplantation was 1 in 9.3ϫ10 5 mononuclear cells in CB grafts and 1 in 6ϫ10 6 mononuclear cells in PBSC grafts from normal adult donors [10] . We developed a multiple linear regression model that allows comparisons of levels of human hematopoietic cell engraftment in NOD/SCID mice. We found that the short-term (4-8 weeks) engraftment potential per transplanted CD34 ϩ cell was ϳ50-fold higher for CB than for PBSC from cancer patients undergoing chemotherapy [11] . Because the longterm engraftment capacity of hematopoietic grafts carries important implications for clinical transplant and gene therapy [3, 4] , the present investigation further characterized the engraftment kinetics resulting from CD34 ϩ cells of these two sources during the whole lifespan of the murine recipients. In addition, because the number of active stem cells also has significant implications for gene therapy [12] , we quantified the frequency of long-term engrafting cells using a competitive repopulation assay with binomial variancecovariance modeling [13] [14] [15] . Results from the latter assay allowed the estimation of the average proliferative capacity of individual long-term engrafting cells.
PATIENTS AND METHODS

Human cells
CB samples from placentas of healthy newborns collected by Poietic Technologies (Gaithersburg, MD) were purchased. PBSC were obtained as small aliquots from goodyield (Ͼ2ϫ10 6 CD34 ϩ cells collected/kg) autologous leukapheresis mobilized blood products from cancer patients undergoing chemotherapy at the Johns Hopkins Hospital under an institutional review board-approved protocol. The PBSC mobilization regimen was cyclophosphamide (4 gm/m 2 ) followed by G-CSF (10 g · kg -1 · day -1 until the day of the single large-volume leukapheresis [16] . Both CB and PBSC were thawed using the method of Rubinstein et al. [17] . Viability was Ͼ95% in all samples by trypan blue exclusion. CD34 ϩ cell purification was performed using immunomagnetic beads, as previously described [18, 19] .
DESIGN
Eighty nonobese diabetic/LtSz-scid/scid (NOD/SCID) mice were randomized to receive either CB or autologous PBSC [20] . A large concurrent control experimental design with multiple timepoints was chosen instead of several small sequential experiments. The large sample size and the concurrent controlled nature of this experiment tended to increase internal validity and protect against random error and potential bias arising from such factors as day-to-day experimental error or recipient bias [21] . Cells pooled from 20 CB or four PBSC specimens were used to estimate the differences in engraftment and stem cell frequencies between these two types of clinically relevant grafts rather than variability among individual CB or PBSC samples. Pooling the cells before transplantation is particularly important in this kinetic study, since it prevents significant influence from peculiarities in any sample on the timedependent engraftment variables (see "Statistical analysis").
TRANSPLANTATION OF HUMAN CELLS
Human CD34
ϩ cells were transplanted by tail vein injection into sublethally irradiated (350 cGy using a 137 Cs g-irradiator) 6-to 8-week-old NOD/SCID mice. All mice received human interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and stem cell factor ([SCF]10 g of each/dose; Amgen, Thousand Oaks, CA) intraperitoneally every Monday, Wednesday, and Friday post-transplantation, to maximize levels of human cells in the engrafted human-murine chimeras [11] . Mice were bred and maintained in pathogen-free conditions as described [19, 20] . Animal experiments were approved by the Animal Care and Use committee of the Johns Hopkins Medical Institutions. Mice were killed 2-20 weeks after transplantation, as specified, for removal of organs. Week 20 after transplantation was chosen as the latest time point, because the average lifespan of this mouse strain is only ϳ8 months due to its high incidence of thymic lymphomas [20] .
Analysis of human cell engraftment
Single-cell suspensions were prepared from removed spleens. Bone marrow cells were obtained by flushing both the removed femurs and tibiae from each animal. Cells were counted using a Coulter Z1 cell counter (coefficient of variance Ͻ3%; Coulter, Miami, FL). Because these four bones contain ϳ25% of the total marrow volume of a mouse [22] , the total number of marrow cells was estimated by multiplying the number of cells obtained by 4. Human cells were enumerated and cell lineages determined by 3-color flow cytometry (fluorescence-activated cell sorter [FACS] ; Becton Dickinson, San Jose, CA) using murine monoclonal antihuman leukocyte antibodies as described previously (Fig. 1 ) [18, 19] . Estimates of measurement error for the percentage of human CD45 ϩ cells in the chimeras were obtained from repeated, independent sampling of a 40:60 and a 1.5:98.5 mixture of human to murine leukocytes. These error estimates were used for adjusting variances, as described in Table 1 . Colony-forming assays were performed using described methods that were shown to be selective for the growth of human colonies in a murine cell background [19, 23] .
Statistical analysis
The number of primitive cells that contributed to longterm engraftment was estimated using the binomial variance-covariance model developed by Stone and Harrison et al. [13] [14] [15] . This model does not quantify those quiescent hematopoietic cells that may be present but do not contribute to engraftment. Therefore, we adopted the term "contributory cells" used by Stone and Harrison et al. and called these cells contributory engrafting cells (CECs). In this study, instead of competition between murine cells of different genotypes, we measured the competition between human vs. murine hematopoietic cells. For cohort of recipients of identical aliquots of the same CB or PBSC CD34 ϩ cell pool, the percentage of human CD45 ϩ (murine CD45 -) cells in the marrow or spleen was measured by flow cytometry. Statistically, the higher the number of stem cells in the aliquots, the lower the variability in the percentage of human CD45
ϩ cells in the chimeras (e.g., the sampling variability of 50 stem cells is lower than that of five stem cells).
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Separate calculations were made for the CB and PBSC groups and for the marrows and spleens of the chimeras. For example, for the marrows of the recipients of PBSC, we calculated: mean ϭ the average % of human CD45 ϩ cells in their marrows; SD ϭ the standard deviation of the % of human CD45 ϩ cells. The estimate of 1/π m is then given by the formula: (mean)(100-mean)/SD 2 , where π m is the probability that two cells drawn independently at random from the marrow of a recipient were produced by the same CEC. Using this binomial formula avoids the unverified assumption that the proliferative capacity of each murine CEC is equivalent to that of each human CEC [13, 14] .
An alternative approach to the estimation of the number of CEC contributing to two cell compartments (e.g., marrow and spleen) is based on the covariance of the proportions of human CD45 ϩ cells in the two compartments of each recipient [13, 14] . For this, the analogue of π m would be π ms , which is the probability that a randomly sampled cell from the marrow and a randomly sampled cell from the spleen descended from the same CEC.
An advantage of using covariance-based, rather than variance-based, estimates is that there is no bias (arising from experimental error or any other source of error that is uncorrelated in the two compartments) to be removed. However, its validity in this context rests on the assumption that the development of the CD45 ϩ cells in the two compartments is highly correlated (i.e., higher engraftment in the spleen of a chimera accompanied higher engraftment in its marrow) [14] . In human/murine xenotransplants, high engraftment in marrow was associated with an enlarged spleen attributable to compensatory murine hematopoiesis [23] . Thus, the percentage of human cells in the spleen of a highly engrafted animal could occasionally be decreased by the increase in number of murine cells in the denominator. This paradox may decrease the covariance of the proportions of human cells in the marrows and spleens (see footnote in Table 1 ).
RESULTS
Short-and long-term engraftment potential of CB vs. PBSC
For the first cohort, 40 mice were each transplanted intravenously with 0.5 million CD34 ϩ CB cells (96% CD34 ϩ ) from a pool of CB cells assembled from 20 CB specimens. In the second cohort, another 40 mice were each transplanted with 3 million CD34 ϩ cells from a pool of PBSC. CD34 ϩ cells were purified from a pool of PBSC obtained from four patients with Ewing's sarcoma or breast cancer who had received 3-6 cycles of chemotherapy before leukapheresis. All the PBSC were obtained from individual collections, which contained Ͼ2ϫ10 6 CD34 ϩ cells/kg. The pooled PBSC preparation of CD34 ϩ cells was 96% CD34 ϩ . Chimeras were killed at 2, 4, 8, 14, or 20 weeks after transplantation for detailed immunophenotypic analysis of human cells in their marrows and spleens. As shown in Figure 2 , high levels of human cell engraftment were found in the marrows and spleens of the chimeras of both cohorts in the first 4 weeks after transplantation. For the cohort that received PBSC, however, the levels of engraftment in both marrows and spleens dropped significantly by 8 weeks after transplantation and remained lower at all later time points.
In contrast, the levels of engraftment were maintained at relatively high levels for the chimeras that received CD34 ϩ CB cells, even though sixfold fewer CD34 ϩ cells had been transplanted. These results were consistently observed at multiple long-term time points (Ն8 weeks).
Kinetics of different populations of human hematopoietic cells
Comparisons were then made between the chimeras that received CD34 ϩ cells from CB vs. PBSC in engraft- Figure 3A , at 2-8 weeks after transplantation, large numbers of human CD19 ϩ (pan-) B lymphoid cells were found in the marrows and spleens of the chimeras, which had received either CB or PBSC. Many human CD20
ϩ (phenotypically mature) B lymphoid cells were found in their marrows at 4-8 weeks after transplant, as well as in their spleens at 8 weeks after transplant. At 14-20 weeks after transplant however, the numbers of
CD19
ϩ and CD20 ϩ human cells had decreased exponentially in the marrows and spleens of the chimeras that had received CD34
ϩ PBSC. This is in contrast to the chimeras that had received CD34 ϩ CB cells in which high (stable) numbers of CD19 ϩ and CD20 ϩ B lymphoid cells were found at late as well as earlier time points.
Throughout the 20 weeks of study, large numbers of CD13 ϩ and CD15 ϩ human myeloid cells were found in the marrows and spleens of the chimeras that had received CD34 ϩ CB cells (Fig. 3B) . On the other hand, the number of CD13 ϩ and CD15 ϩ myeloid cells in the spleens and CD15 ϩ cells in the marrows of the chimeras that had received CD34
ϩ PBSC decreased exponentially Ͼ8 weeks after transplant. After 8 weeks, the cells found in the marrows of chimeras that had received CD34 ϩ PBSC were mostly CD13 ϩ CD15 Ϫ cells. The numbers of stem/progenitor cells in these chimeras were also compared. As shown in Fig. 4 , the numbers of CD34 ϩ cells in the marrows of the chimeras that had received CD34 ϩ CB were persistently higher than the initial inoculum (i.e., 0.5 million). In contrast, for the chimeras that received (3 million) CD34
ϩ PBSC, the number of CD34 ϩ cells in the marrows decreased exponentially in the first 8 weeks after transplantation, then stayed at a relatively low (Ͻ1% of the cell number transplanted), steady level through week 20. Similar kinetics were observed for the total number of colony-forming cells (CFCs) in the marrows of the chimeras as measured by colony-forming assays. Although the numbers of CFCs were similar between the two cohorts at 2 weeks after transplantation, this number decreased continuously thereafter for the chimeras that had received CD34
ϩ PBSC (Fig. 4) . The distribution of the subclasses of CFCs also differed. In the first 4 weeks after transplantation, most of the CFCs in the chimeras that received CD34 ϩ PBSC were CFU-E, whereas most of the CFCs in chimeras that received CD34 ϩ CB were earlier progenitors (e.g., CFU-GEMM; Table 2 ). Thereafter, all types of progenitors were present in the chimeras that received CD34 
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CB, except for CFU-E. In contrast, the only type of progenitor detected in chimeras Ͼ14 weeks after transplantation with CD34 ϩ PBSC was CFU-GM. Note that, as described earlier, complete human erythropoietic development was poorly supported in these mice [9, 19] .
Frequency of long-term CECs in CB vs. PBSC
After the first phase of engraftment [24] , 20 mice (in addition to the four mice killed at 8 weeks) from each cohort were killed at 8-10 weeks after transplant to quantify the number of long-term CECs by using the binomial competitive repopulation model. The estimated frequencies of longterm CECs were 1 in 2.5ϫ10 5 CD34 ϩ CB cells and 1 in 2ϫ10 6 CD34 ϩ PBSC, an eightfold difference (Table 1 and APPENDIX). These estimates were very similar for marrows and spleens. Calculations using the covariance method also gave a similar result for the number of CECs in PBSC. The frequency of long-term CECs in CD34
ϩ CB was not estimated using the covariance model because the percentage of human CD45
ϩ cells in the marrows and spleens was not highly correlated (r Ͻ 0.75), and the proliferative capacity of CB CECs could not be assumed to be similar to that of murine CECs (Table 1 and APPENDIX) [15] .
Proliferative capacity of individual CECs
Each CB long-term CEC resulted in ϳ20 million human CD45 ϩ cells in the chimeras' marrows and ϳ9 million in their spleens at 8-10 weeks after transplant. In contrast, each PBSC long-term CEC at 8-10 weeks resulted in only ϳ1.2 and ϳ0.8 million CD45
ϩ human cells in the chimeras' marrows and spleens, respectively. Thus, the proliferative capacity was ϳ12-to 15-fold higher for each CB long-term CEC over each PBSC long-term CEC. Taken together with the difference in the frequency of long-term A B g CEC, CD34 ϩ cells from CB had an ϳ100-fold higher engraftment potential over CD34 ϩ cells from PBSC.
DISCUSSION
Both CB and autologous PBSC are now used widely for clinical transplantation. In some patients, there is a need to choose between a transplant graft of autologous PBSC or allogeneic CB. Our results indicate a remarkable difference in the number and function of transplantable hematopoietic cells in the CD34 ϩ cells from these two sources. In this study, the engraftment kinetics of CB vs. autologous PBSC from cancer patients undergoing chemotherapy were reminiscent of the two phases of engraftment following murine syngeneic bone marrow transplantation [24] . Jones et al. suggested that the first unsustained short-term phase was produced by committed progenitors, whereas the second sustained long-term phase was due to pluripotent stem cells.
When compared with CD34
ϩ cells from autologous PBSC on a per-cell basis, CD34 ϩ cells from CB had an ϳ10-fold higher short-term (2-4 weeks) engraftment potential. Thus, transplantation of a PBSC graft containing ϳ10-fold more CD34 ϩ cells (vs. a CB graft) would result in similar levels of B lymphoid, myeloid, and erythroid engraftment in chimeras assessed at 2-4 weeks after transplant. This prediction was based on our prior report that there was a linear dose-response relationship between the number of human CD34 ϩ cells transplanted and the number of human cells engrafted in the chimeras [11] . If these results are extrapolated to human hematopoietic cell transplantation and adjusted for the usual ϳ50-fold higher numbers of CD34 ϩ cells harvested in an autologous PBSC graft vs. a CB graft, our results indicate that autologous CD34 ϩ PBSC may be a richer source of hematopoietic cells for rapid erythroid, granulo-monocytic, and B lymphoid reconstitution. This is in agreement with the clinical observation that autologous PBSC provided more rapid trilineage (erythroid, granulomoncytic, and lymphoid) blood cell count recovery in patients than did CB [1, 2] .
In our experiments, 32 chimeras of each group (CB or PBSC) were killed Ͼ8 weeks after transplantation. When compared with CD34 ϩ cells from CB on a per-cell basis, CD34 ϩ cells from autologous PBSC had a much lower longterm (Ͼ8 weeks, second phase) engraftment potential. The high level of engraftment in the first 4 weeks for the cohort that received autologous PBSC proved that CD34 ϩ cells homed and proliferated in the NOD/SCID bone marrow microenvironment. Nevertheless, the engraftment was not sustained; only very low levels of human CD19 ϩ and CD20 ϩ B lymphoid cells, as well as CD13 ϩ and CD15 ϩ myeloid cells, were detected in the marrows and spleens of the 32 chimeras that had received CD34
ϩ PBSC Ͼ8 weeks after transplant. Moreover, Ͼ1% of the original transplanted number of CD34 ϩ cells from PBSC were found in the marrows Ͼ8 weeks after transplant. The number of CFCs, as assayed by colony-forming assays, in the marrows also decreased exponentially after 2 weeks. Overall, we found that CB CD34 ϩ cells had an ϳ120-fold higher long-term engraftment potential on a per-cell basis when compared with PBSC CD34 ϩ cells. Even after adjustment for the usual ϳ50-fold higher number of CD34 ϩ cells in a PBSC (compared with a CB) transplant graft, CB is a more potent source for long-term lympho-hematopoietic engraftment in this chimera model.
The higher long-term engraftment potential of CB vs. PBSC could be due to a higher frequency of long-term CECs or a higher proliferative capacity for each CEC or both. This was tested using the competitive repopulation analysis with binomial variance-covariance modeling using data from the 48 chimeras that were killed 8-10 weeks after transplant. We found that long-term CECs were not only enriched (approximately eightfold) in the CD34 ϩ fraction of CB (compared with PBSC), but also had an ϳ15-fold higher proliferative capacity per CEC. The low frequency of longterm CECs in CD34 ϩ PBSC suggested that only a very tiny fraction of the cyclophosphamide plus G-CSF-mobilized CD34
ϩ PBSC contributed to long-term engraftment. Moreover, the proliferative capacity of each CEC was reduced, which could be explained by age effect (i.e., adults donated PBSC) [5, 6] , difference in progenitor cell cyling activity [25, 26] , or prior chemotherapy or cytokine therapy (given to the patients whose PBSC were tested) [7] . Long-term engraftment may not be a significant concern in the use of hematopoietic cells for autologous hematopoietic rescue after high-dose therapy for solid cancers, since eventual resurgence of non-transplanted endogenous stem cells is possible after non-myeloablative chemotherapy. In contrast, these findings may have important implications for the use of autologous PBSC rescue for myeloablative therapies for hematologic malignancies (e.g., chronic myeloid leukemia or acute myeloid leukemia) [27, 28] , as well as for gene therapy with autologous PBSC [3, 29] . First, these clinical transplantation situations require sustained, long-term immunohematopoietic reconstitution (or durable high-level gene expression). Second, low-level long-term engraftment may provide a competitive advantage to abnormal clones resulting from prior exposure to chemotherapy. This biology may contribute to the unexpectedly high incidence of myelodysplastic syndrome or late autograft failure observed in nonHodgkin's lymphoma patients, despite large numbers of CFU-GM in the autologous PBSC grafts [30] [31] [32] . Without transplantation, these patients have been considered to be at minimal risk for the development of myelodysplastic syndrome or marrow failure [32] . In this study, CD34 ϩ cells from CB had a higher frequency of long-term CECs and a higher proliferative capacity of each long-term CEC than Figure 4 .
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CD34 ϩ cells from PBSC. This extends the prior in vitro evidence that CB may be a preferred alternative clinical source of hematopoietic cells for long-term reconstitution, ex vivo expansion, and gene therapy [1] .
This report confirms that only a very small number (ϳ0.5-4 per 10 6 CD34 ϩ cells) of human hematopoietic cells contribute to long-term engraftment (observed in our 48 chimeras) at a given time, as shown in murine or feline hematopoiesis [12, 33] . This may explain the wide variation observed over time (Ͻ0.001-0.03%; i.e., Ͼ1.5 log) in the frequency of vector DNA-positive peripheral blood granulocytes after autologous transplants of CB CD34 ϩ cells that were transduced with an ADA-containing retrovirus in the setting of low transduction efficiency [34, 35] . The observed frequency of transduced progeny approximates a binomial distribution with a mean equal to overall transduction efficiency and a variance inversely proportional to the number of CECs. Thus, even if the overall transduction efficiency can be increased in the future to as high as ϳ10% (e.g., by myeloablation and increased gene transfer efficiency) [34] for some white cell or megakaryocytic disorders (e.g., chronic granulomatous disease and Glanzmann's thrombasthenia) [28, 36] , life-threatening infection or bleeding may remain a real danger during the time period when the observed frequency of transduced cells is low.
In conclusion, CD34 ϩ cells from CB grafts collected from healthy newborns provided sustained long-term multilineage engraftment of immunodeficient mice, whereas CD34 ϩ cells from autologous PBSC grafts collected from cancer patients undergoing chemotherapy provided early multilineage engraftment that was not well sustained. Only a small number of CECs accounted for the majority of the mature hematopoietic cells. In comparison to CD34 ϩ cells from autologous PBSC, long-term CECs were enriched in the CD34 ϩ fraction of CB, and each long-term CB CEC had a higher inherent multilineage proliferative capacity. These findings may be important in the development of strategies for clinical hematopoietic cell therapy and hematopoietic stem cell biology in general.
ACKNOWLEDGMENTS
We thank L. Schultz for providing breeder pairs of NOD/SCID mice and valuable consultation, Amgen (Thousand Oaks, CA) for providing human growth factors, S. Piantadosi and S. Sharkis for reviewing the manuscript, and Laura Domina for assisting in manuscript preparation. Assume that all CECs of the same type contribute equally to the CD45 ϩ cells that were sampled, for the marrows of the chimeras that received PBSC. where 1.8ϫ10 6 was the average total number of human CD45 ϩ cells in the marrow of a chimera (i.e., Cpbsc ϫ Npbsc), 89.4ϫ10 6 was the average total number of murine CD45 ϩ marrow cells (i.e., Cscid ϫ Nscid), and 91.2ϫ10 6 was the average total number of CD45 ϩ (human ϩ murine) marrow cells.
APPENDIX
Assuming Cpbsc Ϸ Cscid, from equation (1.1), Cpbsc Ϸ Cscid Ϸ 1.2ϫ10 6 . Then, Nscid Ϸ 74.5 and Npbsc Ϸ 1.5 (i.e., 0.5 CECs in 10 6 CD34 PBSC). The Npbsc estimated by this variance method approximates very well that estimated using the covariance method (Npbsc ϭ 1.8) as shown in Table 1 , assuming that Cpbsc Ϸ Cscid.
If the assumption above is incorrect and if Cpbsc Ͼ Cscid, then Npbsc will be Ͻ1. This is impossible since at least 1 CEC is necessary to produce the human CD45 ϩ cells detected. If Cpbsc Ͻ Cscid, then 1.8 ϫ Cpbsc will be Ͻ89.4 ϫ Cscid. Then, equation (1.1) will also estimate Cscid Ϸ 1.2ϫ10 6 and Cpbsc Ϸ 1.2ϫ10 6 . Similarly, for marrows of the chimeras that received CB:
where 39.3ϫ10 6 was the average total number of human CD45 ϩ cells in the marrow of a chimera, 62.5ϫ10 6 was the average total number of murine CD45 ϩ marrow cells, and 101.6ϫ10 6 was the average total number of CD45 ϩ (human ϩ murine) marrow cells.
Because Ccb is possibly greater than Cpbsc, whereas Cscid should be relatively constant in mice with the same genetic background, we use the Cscid estimated above (i.e., Cscid ϭ 1.2ϫ10 6 
